Maverick Therapeutics is pioneering the next generation of redirected T cell therapeutics in immuno-oncology. Maverick’s highly innovative platform is designed to deliver potent activity with increased tumor specificity and reduced toxicity, resulting in superior therapeutics for cancer patients and improved clinical success. Maverick was founded by MPM Capital with world renowned immunologist Dr. Patrick Baeuerle in 2016, through a spin-out from Harpoon Therapeutics. In early 2017 Maverick announced $125 million of committed funding from Takeda Pharmaceuticals, MPM BioVentures 2014 and the UBS Oncology Impact Fund.
